László Őrfi
Impact in
- Oncology top 2%
- Drug Transport and Resistance Mechanisms
- HER2/EGFR in Cancer Research
- Hematology top 2%
- Chronic Myeloid Leukemia Treatments
Papers in
-
- Cancer therapeutics and mechanisms 9
- Oncology 31
- HER2/EGFR in Cancer Research 10
- Drug Transport and Resistance Mechanisms 7
- Co-authors
- Gÿorgý Kéri (67 shared papers)András Váradi (4 shared papers)Balázs Sarkadi (5 shared papers)Csilla Özvegy‐Laczka (3 shared papers)Dániel Erös (16 shared papers)Axel Ullrich (10 shared papers)István Szabadkai (15 shared papers)Csaba Szántai-Kis (24 shared papers)
- Journals
- Current Medicinal Chemistry (8 papers)Journal of Medicinal Chemistry (5 papers)Bioorganic & Medicinal Chemistry Letters (5 papers)Scientific Reports (4 papers)Journal of Chromatography B (4 papers)
- Partner nations
- HungaryUnited StatesGermany
In The Last Decade
László Őrfi
113 papers receiving 3.4k citations
Peers
Comparison fields: 5 of 139
- Oncology 1.0k
- Hematology 374
- Genetics 268
- Molecular Biology 1.6k
- Infectious Diseases 366
Countries citing papers authored by László Őrfi
This map shows the geographic impact of László Őrfi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by László Őrfi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites László Őrfi more than expected).
Fields of papers citing papers by László Őrfi
This network shows the impact of papers produced by László Őrfi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by László Őrfi. The network helps show where László Őrfi may publish in the future.
Co-authors
The 25 scholars most cited alongside László Őrfi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 118 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Flk-1 as a target for tumor growth inhibition. | 1996 | 293 |
| 2 | 2004 | 292 | |
| 3 | 2009 | 197 | |
| 4 | 2002 | 184 | |
| 5 | 2008 | 175 | |
| 6 | 2004 | 116 | |
| 7 | 2004 | 93 | |
| 8 | 2010 | 90 | |
| 9 | 2005 | 87 | |
| 10 | 2002 | 87 | |
| 11 | 2014 | 78 | |
| 12 | 2014 | 73 | |
| 13 | 2007 | 65 | |
| 14 | 2008 | 64 | |
| 15 | 2012 | 64 | |
| 16 | 2014 | 60 | |
| 17 | 1997 | 57 | |
| 18 | 1998 | 56 | |
| 19 | 2010 | 49 | |
| 20 | 2021 | 48 |
About László Őrfi
László Őrfi is a scholar working on Molecular Biology, Oncology, Organic Chemistry, Computational Theory and Mathematics and Immunology, having authored 118 papers that have together received 3.5k indexed citations. Recurring topics across this work include Computational Drug Discovery Methods (12 papers), HER2/EGFR in Cancer Research (10 papers), Lung Cancer Treatments and Mutations (10 papers), Quinazolinone synthesis and applications (9 papers), Cancer therapeutics and mechanisms (9 papers), Drug Transport and Resistance Mechanisms (7 papers), Synthesis and biological activity (7 papers) and Tuberculosis Research and Epidemiology (7 papers). The work is most often cited by research in Oncology (1.0k citations), Hematology (374 citations), Genetics (268 citations), Molecular Biology (1.6k citations) and Infectious Diseases (366 citations). László Őrfi has collaborated with scholars based in Hungary, United States and Germany. Frequent co-authors include Gÿorgý Kéri, András Váradi, Balázs Sarkadi, Csilla Özvegy‐Laczka, Dániel Erös, Axel Ullrich, István Szabadkai, Csaba Szántai-Kis, Cynthia K. Larive and Henrik Daub. Their work appears in journals such as Current Medicinal Chemistry, Journal of Medicinal Chemistry, Bioorganic & Medicinal Chemistry Letters, Scientific Reports and Journal of Chromatography B.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.